Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

The Shadow Accumulation of Prelude Therapeutics: Why The Obvious Dilution is a Trap

2026-04-24BullishStrongChange from report: -17.2%1M: -13.0%3M: -18.5%

Institutional investors, not retail, drove Prelude's recent stock offering. Major funds like OrbiMed increased their stakes, signaling strong confidence in upcoming clinical catalysts despite the apparent dilution.